Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-06-04
1997-12-30
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514885, A61K 3144
Patent
active
057030880
ABSTRACT:
A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.
REFERENCES:
patent: 2788309 (1957-04-01), Cooper
patent: 2854380 (1958-09-01), Jensen et al.
patent: 3155669 (1964-11-01), Janssen
patent: 3155670 (1964-11-01), Janssen et al.
patent: 3161644 (1964-12-01), Janssen et al.
patent: 3238216 (1966-03-01), Janssen et al.
patent: 3922266 (1975-11-01), Katsube et al.
patent: 3996363 (1976-12-01), Wade et al.
patent: 4228287 (1980-10-01), van der Stelt
patent: 4555504 (1985-11-01), Jones
patent: 4665075 (1987-05-01), Vandenberk et al.
patent: 4839342 (1989-06-01), Kaswan
patent: 4874766 (1989-10-01), Ooms et al.
patent: 4937249 (1990-06-01), Antoku et al.
patent: 5137894 (1992-08-01), New et al.
patent: 5143922 (1992-09-01), Oshima et al.
patent: 5244902 (1993-09-01), Sharp et al.
patent: 5290783 (1994-03-01), Sharp et al.
Akamatsu, et al. "Suppressive Effects of Linoleic Acid on Neutrophil Oxygen Metabolism and Phagocytosis," Investigative Dermatology, 95:271-274 (1990).
Ameisen, et al., "A New Interpretation of the Involvement of Serotonin in Delayed-Type Hypersensitivity," The Journal of Immunology, 142 (9) 3171-3179 (1989).
Arndt, et al., "The Pharmacology of Topical Therapy," Dermatology in General Medicine, 2532-2540 (T. B. Fitzpatrick, et al., Third Edition, McGraw Hill, Inc., New York 1987).
Blozovsky, et al., "Action de la Serotonine de la Reserpine et D'Autres Agents Pharmacologiques sur la Secretion Sudorale. Etudes Hygrophotographiques," Arch. Intern. Pharmacodynamie, 123:58-66 (1959) (Chemical Abstracts, 215049-1.
Burka, et al., "Dopaminergic (Co-Mediator) Modulation of Release of Histamine and SRS-A in the Calf," British Journal of Pharmacology, 58(3) 445P (1976).
Coffman, "The Attenuation by Reserpine or Guanethidine of the Cutaneous Vasoconstriction Caused by Tobacco Smoking," American Heart Journal, 74(2):229-234 (1967); Chemical Abstracts, 67:7624 810019W (1967).
Diezel, et al., "Inhibition of Cutaneous Contact Hypersensitivity by Calcium Transport Inhibitors Lanthanum and Diltiazem," The Journal for Investigative Dermatology, 93:322-325 (1989).
Eyre, "Dopamine Potentiates Anaphylactic Contraction of Pulmonary Vein of Calf," Research Communications in Chemical Pathology and Pharmacology, 22(3) 447-452 (1978).
Fanta, "Calcium-Channel Blockers in Prophylaxis and Treatment of Asthma," The American Journal of Cardiology, 55:202B-209B (1985).
Galli and Hammel, "Unequivocal Delayed Hypersensitivity in Mast Cell-Deficient and Beige Mice," Science, 226:710-713 (1984).
Hellstrand, et al., "Role of Serotonin in the Regulation of Human Natural Killer Cell Cytotoxicity," The Journal of Immunology 139(3) 869-875 (1987).
Klingham, "The Comparative Histopathology of Male-Pattern Baldness and Senescent Baldness," Clinics in Dermatology, 108-118 (1988).
Leysen, et al., "Receptor Binding of R 41 468, A Novel Antagonist at 5-HT.sub.2 Receptors," Life Sciences, 28(9) 1015-1022 (1981).
Login, et al., "Reserpine in a Calcium Channel Antagonist in Normal and GH.sub.3 Rat Pituitary Cells," American Journal of Physiology, 248:E15-E19 (1985).
Mekori, et al., "Studies of the Role of Mast Cells in Contact Sensitivity Responses. Passive Transfer of the Reaction into Mast Cell-Deficient Mice Locally Reconstituted with Cultured Mast Cells: Effect of Reserpine on Transfer of the Reaction with DNP-Specific Cloned T Cells," Cellular Immunology, 109:39-52 (1987).
Mekori, et al., "Reevaluation of Reserpine-Induced Suppression of Contact Sensitivity," J. Exp. Med., 162:1935-1953 (1985).
Mekori, et al., "Characterization of the Interference of T Cell Activation by Reserpine," Cellular Immunology, 124:308-319 (1989).
Moerlein et al, "Effect of Lipophilicity on the In Vivo Localization of Radiolabelled Spiperone Analogues", Int. J. Nucl. Med. Biol. 12(5), 353-56 (1985).
Nakanishi, et al., "Spirohydantoin Derivatives," Chemical Abstracts, vol. 75:437 110315n (1971).
Reynolds, "Martindale, the Extra Pharmacopoeia," The Pharmaceutical Press, (London, 1989).
Schroder, et al., "Transient Absence of C5a-Specific Neutrophil Function in Inflammatory Disorders of the Skin," Investigative Dermatology, 85:194-198 (1985).
Sharpe, et al., "Inhibition of Cutaneous Contact Hypersensitivity in the Mouse with Systemic or Topical Spiperone: Topical Application of Spiperione Produces Local Immunosuppression without Inducing Systemic Neuroleptic Effects," J. Investigative Dermatology, 99(5):594-600 (1992).
Sternberg, et al., "Macrophase Activation by Serotonin (5-HT) is Affected by Interferon y (IFNy) Concentration and is Antagonized by Spiperone and Ketanserin," Fed. Proc. 44(5) 7526 (1985).
Sternberg, et al., "Effect of Serotonin on Murine Macrophages: Suppression of Ia Expression by Serotonin and its Reversal by 5-HT.sub.2 Serotonergic Receptor Antagonists," J. of Immunology, 137(1):276-282 (1986).
Tucker, et al., "Inflammation in Acne Vulgaris: Leukocyte Attraction and Cytotoxicity by Comedonal Material," Investigative Dermatology, 74:21-25 (1980).
Tytgat and Van Asch, "Topical Ketanserin in the Treatment of Decubitus Ulvers: A Double-Blind Study with 2% Ketanserin Ointment Against Placebo," Advances in Therapy 5(4):143-152 (1988).
The Society for Investigative Dermatology, Meeting Program, 51st Annual Meeting, May 2-5, 1990, pp. 1-62.
Gutsche and Pasto, Fundamentals of Organic Chemistry, pp. 233-234, 705-706 (1975).
Arndt Kenneth A.
Galli Stephen J.
Meltzer Peter C.
Razdan Raj K.
Sard Howard P.
Beth Israel Deaconess Medical Center Inc.
Gerstl Robert
LandOfFree
Topical application of spiperone or derivatives thereof for trea does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical application of spiperone or derivatives thereof for trea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical application of spiperone or derivatives thereof for trea will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-202508